At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 124 enrolled
Drug / intervention
250mg rilapladib +1 moredrug
Likely dose
250mg rilapladibfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) on Biomarkers Related to the Pathogenesis and Progression of Alzheimer's Disease
In Brief
A Phase 2 clinical trial evaluating 250mg rilapladib and placebo for Alzheimer's Disease. Completed, enrolled 124 participants across 30 sites in 7 countries.
Detailed Summary
The study is designed to investigate the effects of rilapladib on biomarkers related to the Alzheimer's disease, and cognitive function.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesBulgaria, Canada, Germany, Italy, Norway, Spain, Sweden
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedSep 2011
Enrollment StartOct 2011
Primary CompletionFeb 2013
Study CompletionFeb 2013
TodayJul 2026
First PostedSep 5, 2011
Enrollment StartOct 1, 2011
Primary CompletionFeb 4, 2013
Study CompletionFeb 18, 2013
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 14.8 years ago
Interventions
250mg rilapladibdrug
Experimental Drug
placebodrug
Placebo comparator